Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HMGCR | P04035 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 2/20 | 0.47 |
| ▸ | TPMT | P51580 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4445888 | 0.88 | GAA (0.49) | HTTKDM4EMAPTHPGDLMNA | |
| SCHEMBL3836141 | 0.86 | MAPT (0.64) | HTTKDM4EMAPTHPGDLMNA | |
| SCHEMBL1743592 | 0.85 | ALDH1A1 (0.51) | HTTKDM4EHPGDHSD17B10TPMT | |
| SCHEMBL3645035 | 0.85 | HTT (0.72) | HTTKDM4EMAPTHPGDLMNA | |
| SCHEMBL3617721 | 0.85 | ALDH1A1 (0.55) | HTTKDM4EMAPTHPGDCYP3A4 | |
| SCHEMBL2730020 | 0.85 | ALDH1A1 (0.49) | HTTKDM4EMAPTHPGDLMNA | |
| SCHEMBL1038769 | 0.84 | HTT (0.70) | HTTKDM4EMAPTHPGDLMNA | |
| SCHEMBL28252586 | 0.84 | HTT (0.70) | HTTKDM4EMAPTHPGDLMNA | |
| SCHEMBL2793251 | 0.84 | GAA (0.58) | HTTKDM4EMAPTHPGDLMNA | |
| SCHEMBL20724883 | 0.82 | HTT (0.57) | HTTKDM4EMAPTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246496-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2024-12-05 | — | — | WO | disclosed |
| US-10905665-B2 | Chemical modulators of signaling pathways and therapeutic use | DUKE UNIVERSITY (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
| EP-3092307-B1 | MELLEOLIDE-BIOSYNTHESIS GENE CLUSTER AND ITS APPLICATION | FRAUNHOFER GES FORSCHUNG (DE) | 2019-07-03 | — | — | EP | disclosed |
| US-10011821-B2 | Melleolide-biosynthesis gene cluster and its applications | Fraunhofer-Gesellschaft zur Foerderung der angewandten Forshung e. V. (DE) | 2018-07-03 | — | — | US | disclosed |
| US-20160319251-A1 | MELLEOLIDE-BIOSYNTHESIS GENE CLUSTER AND ITS APPLICATIONS | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20090176815-A1 | Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| EP-2069355-A1 | NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2009-06-17 | — | — | EP | disclosed |
| US-20080167332-A1 | Novel Compounds 243 | ASTRAZENECA AB (SE) | 2008-07-10 | — | — | US | disclosed |
| WO-2008010765-A1 | NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167332-A1 | Novel Compounds 243 | UGT1A10, ABCG2, VKORC1L1 | HTT 1268/4885KDM4E 2805/4885MAPT 3192/4885 |
| US-20090176815-A1 | Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity | ACKR3, CCR2, CCR5 | HTT 3584/4885KDM4E 4622/4885MAPT 4798/4885 |
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | SFRP1, FZD7, WNT1 | HTT 4702/4885KDM4E 2637/4885MAPT 3433/4885 |
| US-10905665-B2 | Chemical modulators of signaling pathways and therapeutic use | SFRP1, FZD7, WNT1 | HTT 4702/4885KDM4E 2637/4885MAPT 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.